Compare · ANL vs NVO
ANL vs NVO
Side-by-side comparison of Adlai Nortye Ltd. (ANL) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANL and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 265.2x ANL ($840.1M).
- Both names hit the wire about 5 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 7 for ANL).
- Company
- Adlai Nortye Ltd.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $840.1M
- $222.81B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 5
- 5
- Recent ratings
- 7
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ANL
- SEC Form 6-K filed by Adlai Nortye Ltd.
- Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
- New insider Sawhney Roger claimed ownership of 9,838 units of American Depositary Shares (SEC Form 3)
- Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
- Cantor Fitzgerald initiated coverage on Adlai Nortye Ltd.
- Director Ji Ping acquired 136,667 units of American Depository shares (SEC Form 4)
- New insider Ye Xiaofeng claimed ownership of 159,455 units of American Depositary Shares (SEC Form 3)
- SEC Form 3 filed by new insider Tse Alan Ming Lun
- Oppenheimer initiated coverage on Adlai Nortye Ltd. with a new price target
- CEO Lu Yang sold $132 worth of American Depositary Shares (10 units at $13.18), decreasing direct ownership by 0.01% to 99,990 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S